Karen FFPM - Cyclo Therapeutics Interim Officer
| CYTH Stock | USD 0.68 0.05 6.85% |
Executive
Karen FFPM is Interim Officer of Cyclo Therapeutics
| Address | 6714 NW 16th Street, Gainesville, FL, United States, 32653 |
| Phone | 386 418 8060 |
| Web | https://cyclotherapeutics.com |
Cyclo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.8249) % which means that it has lost $2.8249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (226.6391) %, meaning that it created substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Cyclo Therapeutics' current Return On Tangible Assets is estimated to increase to -1.44. The current Return On Capital Employed is estimated to decrease to -4.4. As of now, Cyclo Therapeutics' Intangible Assets are decreasing as compared to previous years.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marcel Moulaison | Ironwood Pharmaceuticals | N/A | |
| Greg Martini | Ironwood Pharmaceuticals | N/A | |
| Stephen Wargacki | Aquestive Therapeutics | 46 | |
| Cassie Jung | Aquestive Therapeutics | 45 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Sam Schlessinger | Assertio Therapeutics | 42 | |
| Pranav Mehta | Amneal Pharmaceuticals, Class | ||
| Paul Schwichtenberg | Assertio Therapeutics | 53 | |
| Damon JD | Alpha Teknova | 54 | |
| Karen Esq | Intracellular Th | 62 | |
| Ronald Silver | Ironwood Pharmaceuticals | 41 | |
| Andrew Davis | Ironwood Pharmaceuticals | 38 | |
| Jeff Christensen | Assertio Therapeutics | N/A | |
| Glenn David | Phibro Animal Health | 52 | |
| Carl MD | Aquestive Therapeutics | 54 | |
| Robert Arnold | Aquestive Therapeutics | N/A | |
| Molly Dir | Assertio Therapeutics | N/A | |
| Larry Miller | Phibro Animal Health | 60 | |
| MD MBA | Assertio Therapeutics | N/A | |
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
Management Performance
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 |
Cyclo Therapeutics Leadership Team
Elected by the shareholders, the Cyclo Therapeutics' board of directors comprises two types of representatives: Cyclo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclo. The board's role is to monitor Cyclo Therapeutics' management team and ensure that shareholders' interests are well served. Cyclo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Lisjak, Global Development | ||
| Lise MD, Chief Officer | ||
| George Fails, Ex Mang | ||
| Jeffrey Tate, Chief COO | ||
| Scott Fine, CEO Director | ||
| Lori McKenna, Global Advocacy | ||
| E Strattan, Founder Director | ||
| Joshua Fine, CFO Secretary | ||
| Lori Gorski, Global Advocacy | ||
| Karen FFPM, Interim Officer |
Cyclo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -226.64 | ||||
| Return On Asset | -2.82 | ||||
| Operating Margin | (45.78) % | ||||
| Current Valuation | 32.28 M | ||||
| Shares Outstanding | 28.77 M | ||||
| Shares Owned By Insiders | 40.07 % | ||||
| Shares Owned By Institutions | 13.17 % | ||||
| Number Of Shares Shorted | 114.42 K | ||||
| Price To Book | 59.10 X | ||||
| Price To Sales | 18.54 X |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.